“Access” means that patients can get medical treatments that help them live full lives. It’s an issue that is growing in importance as the treatment paradigm shifts for those living with rare and serious bleeding disorders. When new innovations come to market, such as gene therapy, access is weighed by stakeholders who make decisions about which treatments will be covered by insurance or provided by government health services.
Thanks to treatment advances, bleeding disorder patients have options. But depending on where a patient lives, they may not have access to treatments such as coagulation factor replacement therapy. Patients who have hemophilia and conditions such as von Willebrand Disease lack one of the clotting factors involved in coagulation that prevents excessive bleeding.
Replacement factor infusions can help prevent dangerous bleeds. That’s why the World Federation of Hemophilia (WFH) Humanitarian Aid Program is so important. CSL Behring makes an annual donation of international units of coagulation factor therapy and CSL is proud to spearhead efforts to advocate for greater access for the bleeding disorder community.
Watch the video above to learn more about CSL’s commitment to the bleeding disorder community and join us in celebrating World Hemophilia Day.
